Artizan Biosciences Inc.
http://www.artizanbiosciences.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Artizan Biosciences Inc.
Multiple Alliances Expand Brii’s Commitment To Anti-Infectives
China-focused venture goes against tide by acquiring anti-infective assets via multiple deals that will build out its pipeline in an area deprioritized by big pharma.
Venture Funding Deals: Locana Gets Ready To Take On ALS, Huntington's With Gene Editing
The series A fundraising will help Locana bring CRISPR gene editing to diseases with dysfunctional RNA. Artizan and OncoMyx are among the other firms with recent series A rounds.
Asia Deal Watch: BeiGene And Celgene Exit Their Anti-PD-1 Collaboration
The Chinese firm regains all rights to tislelizumab ahead of the closing of Celgene’s merger with Bristol-Myers Squibb. BeiGene also forms cancer JV with US biotech SpringWorks.
Finance Watch: Tetraphase Reorganization Follows Troubled Antibiotic Commercialization Path
Tetraphase's plan to downsize may put the company on the same path as now-bankrupt Achaogen. Also, Bain raises $900m for its second life science fund, Provention calls off post-ADA offering and Oncologie raises $80m series B.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice